The Pathophysiology of Acute Promyelocytic Leukemia

Francesco Lo-Coco; Syed Khizer Hasan

doi:10.1002/9781444327359.ch13

The Pathophysiology of Acute Promyelocytic Leukemia

Francesco Lo-Coco, Syed Khizer Hasan

Fondazione Santa Lucia

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Acute promyelocytic leukemia (APL) is a particular leukemia subset characterized by a unique genetic lesion, i.e. the PML-RARα fusion, and an exquisite response to differentiating agents. Until the late 1980s, APL was considered the most aggressive and rapidly fatal form of acute leukemia. Over the past two decades, important advances have been made into the understanding of APL pathogenesis, as well as in its treatment, such that it has nowadays been converted into the most frequently curable leukemia in adults. APL is regarded as a model disease for the innovative tailored treatment of human leukemia, including differentiation therapy and the use of chromatin remodeling agents and antibody-directed therapy. This chapter summarizes the pathophysiology of APL with special emphasis on its impact on targeted treatment.

Original language	English
Title of host publication	Leukemias: Principles and Practice of Therapy
Publisher	Wiley-Blackwell
Pages	161-168
Number of pages	8
ISBN (Print)	9781405182355
DOIs	https://doi.org/10.1002/9781444327359.ch13
Publication status	Published - Jan 4 2011

Keywords

Acute promyelocytic leukemia
All-trans retinoic acid (ATRA)
Arsenic trioxide
PML-RARα

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1002/9781444327359.ch13

Fingerprint Dive into the research topics of 'The Pathophysiology of Acute Promyelocytic Leukemia'. Together they form a unique fingerprint.

Cite this

@inbook{1104658bff124e84a673b33fa47c2805,

title = "The Pathophysiology of Acute Promyelocytic Leukemia",

abstract = "Acute promyelocytic leukemia (APL) is a particular leukemia subset characterized by a unique genetic lesion, i.e. the PML-RARα fusion, and an exquisite response to differentiating agents. Until the late 1980s, APL was considered the most aggressive and rapidly fatal form of acute leukemia. Over the past two decades, important advances have been made into the understanding of APL pathogenesis, as well as in its treatment, such that it has nowadays been converted into the most frequently curable leukemia in adults. APL is regarded as a model disease for the innovative tailored treatment of human leukemia, including differentiation therapy and the use of chromatin remodeling agents and antibody-directed therapy. This chapter summarizes the pathophysiology of APL with special emphasis on its impact on targeted treatment.",

keywords = "Acute promyelocytic leukemia, All-trans retinoic acid (ATRA), Arsenic trioxide, PML-RARα",

author = "Francesco Lo-Coco and Hasan, {Syed Khizer}",

year = "2011",

month = jan,

day = "4",

doi = "10.1002/9781444327359.ch13",

language = "English",

isbn = "9781405182355",

pages = "161--168",

booktitle = "Leukemias: Principles and Practice of Therapy",

publisher = "Wiley-Blackwell",

}

TY - CHAP

T1 - The Pathophysiology of Acute Promyelocytic Leukemia

AU - Lo-Coco, Francesco

AU - Hasan, Syed Khizer

PY - 2011/1/4

Y1 - 2011/1/4

N2 - Acute promyelocytic leukemia (APL) is a particular leukemia subset characterized by a unique genetic lesion, i.e. the PML-RARα fusion, and an exquisite response to differentiating agents. Until the late 1980s, APL was considered the most aggressive and rapidly fatal form of acute leukemia. Over the past two decades, important advances have been made into the understanding of APL pathogenesis, as well as in its treatment, such that it has nowadays been converted into the most frequently curable leukemia in adults. APL is regarded as a model disease for the innovative tailored treatment of human leukemia, including differentiation therapy and the use of chromatin remodeling agents and antibody-directed therapy. This chapter summarizes the pathophysiology of APL with special emphasis on its impact on targeted treatment.

AB - Acute promyelocytic leukemia (APL) is a particular leukemia subset characterized by a unique genetic lesion, i.e. the PML-RARα fusion, and an exquisite response to differentiating agents. Until the late 1980s, APL was considered the most aggressive and rapidly fatal form of acute leukemia. Over the past two decades, important advances have been made into the understanding of APL pathogenesis, as well as in its treatment, such that it has nowadays been converted into the most frequently curable leukemia in adults. APL is regarded as a model disease for the innovative tailored treatment of human leukemia, including differentiation therapy and the use of chromatin remodeling agents and antibody-directed therapy. This chapter summarizes the pathophysiology of APL with special emphasis on its impact on targeted treatment.

KW - Acute promyelocytic leukemia

KW - All-trans retinoic acid (ATRA)

KW - Arsenic trioxide

KW - PML-RARα

UR - http://www.scopus.com/inward/record.url?scp=84885497524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885497524&partnerID=8YFLogxK

U2 - 10.1002/9781444327359.ch13

DO - 10.1002/9781444327359.ch13

M3 - Chapter

AN - SCOPUS:84885497524

SN - 9781405182355

SP - 161

EP - 168

BT - Leukemias: Principles and Practice of Therapy

PB - Wiley-Blackwell

ER -